U.S. Computational Biology Market - By Tool, By Application, By Services, By End Use - Forecast, 2025 - 2034

U.S. Computational Biology Market Size

The U.S. computational biology market was valued at USD 3.2 billion in 2024. The market is expected to reach from USD 3.5 billion in 2025 to USD 9.5 billion in 2034, growing at a CAGR of 11.7% during the forecast period, according to the latest report published by Global Market Insights Inc. The high market growth is attributed to the ongoing advancements in artificial intelligence in healthcare and machine learning, growing genomic and proteomic research, increasing drug discovery and development activities, and rising adoption of personalized and precision medicine, among other contributing factors.

Computational biology is the interdisciplinary field of science that deals with the use of computing methods, software algorithms, and mathematical frameworks for the analysis and the derivation of meaning from biological data. It is vital in the comprehension of complex biological systems, e.g., genomes, proteins, and cellular networks. The department merges biology, computer science, mathematics, and statistics to fuel the research and medical practice advancement.
 

Some of the major U.S. computational biology companies are Thermo Fisher Scientific, BIO-RAD, DASSAULT SYSTEMES, Illumina, QIAGEN, and Schrödinger. These firms not only keep their market strong by going on with a constant innovation in their products and services, but they also achieve this through their regional presence and large investments in research and development initiatives.
 

The market has increased from USD 1.7 billion in 2021 and reached USD 2.7 billion in 2023, with the historic growth rate of 25.1%. The growth is attributed to the rising adoption of advanced computational tools in genomics and proteomics, increasing investment in bioinformatics and AI-driven research, the expansion of precision medicine initiatives, and the growing demand for faster drug discovery and development processes in the country.
 

The surge in genomics, proteomics, and other omics research has fuelled the demand for computational biology tools. Researchers increasingly rely on bioinformatics software and algorithms to analyse large datasets, enabling faster identification of biomarkers, disease pathways, and potential drug targets. As data complexity continues to grow, this trend is expected to further accelerate market expansion.
 

In addition, pharmaceutical and biotechnology companies in the U.S. are investing heavily in computational biology to streamline R&D processes. Techniques such as in silico modeling, molecular docking, and simulation reduce the need for costly laboratory experiments. This increased efficiency in identifying drug candidates and predicting clinical trial outcomes is driving strong growth in market demand.
 

Furthermore, the integration of AI and machine learning into computational biology is transforming drug discovery and disease modeling. These technologies enable more efficient prediction of protein structures, simulation of biological systems, and identification of therapeutic candidates. The resulting enhanced precision and reduced time-to-market are driving adoption across pharmaceutical and biotechnology companies.
 

U.S. Computational Biology Market Trends

The U.S. computational biology industry is experiencing several notable trends shaping its growth and development. Factors such as the integration of AI and deep learning in biological modeling, the expansion of cloud-based bioinformatics platforms, the rise of multi-omics data integration, and increased collaboration between academia and industry, among others, are collectively driving the industry growth.
 

• AI technologies and deep learning algorithms are being progressively leveraged for the prediction of protein folding, gene expression analysis, and the simulation of biological systems that are complex. Consequently, this trend is reflecting the use of both accuracy and efficiency in the application of drug discovery, structural biology, and diagnostics. The use of AI-based automation is gradually making its presence felt in the processing of computational biology workflows.
   
• Cloud computing is revolutionizing biological research in terms of data storage, sharing, and computational capacity. The U.S. institutions and the biotech companies are progressively turning to cloud-based platforms that are suitable for large-scale genomic data analysis and collaborative work. The turnaround from traditional to digital mode thus enables scalability, real-time access, and cost-effective management of extensive biological datasets.
   
• In addition, collaborations between U.S. universities, pharmaceutical companies, and computational biology startups are accelerating innovation. Joint research projects and shared data ecosystems are fostering the development of new algorithms and predictive models. This trend is bridging theoretical biology with practical applications in drug discovery and healthcare, thereby supporting sustained market growth.
   

U.S. Computational Biology Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on the tool, the U.S. computational biology market is segmented into analysis software and services, databases, and hardware. The analysis software and services segment has asserted its dominance in the market by securing a significant market share of 45.4% in 2024 owing to the growing demand for advanced data analytics tools, integration of AI-driven algorithms for biological modeling, and the increasing reliance on cloud-based platforms for large-scale genomic and proteomics data interpretation. The segment is expected to exceed USD 4.4 billion by 2034, growing at a CAGR of 11.9% during the forecast period.
 

On the other hand, the databases segment is expected to grow with a CAGR of 12%. The growth of this segment is driven by the rising volume of biological and omics data, increasing adoption of centralized data repositories for research collaboration, and the growing need for efficient data management and retrieval systems in genomics and drug discovery.
 

• The analysis software and services segment continues to dominate the market. The exponential growth of genomic, proteomic, and transcriptomic data has created high demand for advanced analysis software and services. Researchers require powerful computational tools to process and interpret large datasets efficiently. This data surge drives adoption of both software solutions and outsourced analytical services.
   
• Cloud-based software and Software-as-a-Service (SaaS) offerings provide scalable, cost-effective solutions for data analysis. U.S. research institutions and companies prefer these models for remote collaboration, data sharing, and on-demand computational power. This trend accelerates the growth of analysis software and service providers.
   
• The databases segment held a revenue of USD 1.1 billion in 2024, with projections indicating a steady expansion at 12% CAGR from 2025 to 2034. The segmental growth is mainly due to the rising production of large-scale genomic, proteomic and multi-omics data that needs to be stored and managed properly. Moreover, the requirement for data repositories that are centralized, accessible, and interoperable is the major factor that supports research activities, and the cross-licenses among the biotech and pharmaceutical companies that are the results of it.
   
• The hardware segment accounted for significant revenue in 2024 and is anticipated to grow at a CAGR of 10.5% over the forecast period. The segment is driven by the rising need for high-performance computing systems and specialized laboratory instruments to handle complex biological simulations and large datasets. Additionally, advancements in sequencing machines, imaging devices, and data processing infrastructure are boosting the adoption of hardware solutions in research and clinical applications.
   

Based on application, the U.S. computational biology market is segmented into cellular & biological simulation, drug discovery & disease modelling, preclinical drug development, clinical trials, and human body simulation software. The cellular & biological simulation segment dominated the market in 2024, accounting for USD 1.1 billion and is anticipated to grow at a CAGR of 11.8% during the forecast period.
 

• The increasing availability of HPC resources enables the simulation of complex cellular processes at higher speed and accuracy. Researchers can model entire biological systems in silico, reducing reliance on costly lab experiments. This capability drives adoption in both academia and industry.
   
• Further, simulations of cellular responses allow researchers to predict drug efficacy and toxicity before clinical trials. This reduces the time, cost, and risk associated with traditional in vitro and in vivo testing. The efficiency of simulation platforms fuels market growth.
   
• The drug discovery & disease modelling segment accounted for significant revenue in 2024 and is anticipated to grow at a CAGR of 12.1% over the forecast period. The growth of drug discovery and disease modeling is driven by the increasing use of multi-omics data to identify novel therapeutic targets and understand complex disease mechanisms. Additionally, the integration of AI and machine learning enhances predictive accuracy, enabling faster identification of potential drug candidates.
   
• The preclinical drug development segment held a revenue of USD 463.4 million in 2024, with projections indicating a steady expansion at 11.5% CAGR from 2025 to 2034. The segmental growth is driven by the rising demand for in silico models to reduce reliance on animal testing and accelerate early-stage research. Furthermore, advanced bioinformatics tools enable precise simulation of drug behaviour and toxicity, improving candidate selection before clinical trials.
   
• The clinical trials segment accounted for significant revenue in 2024 and is anticipated to grow at a CAGR of 11.3% over the forecast period. The growth of the segment is driven by the use of predictive analytics for patient stratification and optimized trial design, enhancing efficiency and success rates. Additionally, integration of real-world data and biomarkers supports more targeted and adaptive study protocols.
   
• The human body simulation software segment accounted for significant revenue in 2024 and is anticipated to grow at a CAGR of 8.4% over the forecast period. The segment is driven by the need for virtual testing of drug effects and disease progression, reducing reliance on costly in vivo experiments. It also enables personalized medicine by modeling responses across diverse patient populations.
   

Based on services, the U.S. computational biology market is segmented into contract and in-house. The contract segment dominated the market in 2024, accounting for USD 1.9 billion and is anticipated to grow at a CAGR of 12% during the forecast period.
 

• The pharmaceutical and biotech companies are outsourcing the computational biology work, which they are doing through contract service providers. They are aiming to reduce the expenses for infrastructure and staffing. This approach allows companies to focus internal resources on core research while leveraging specialized expertise externally.
   
• Moreover, contract service providers facilitate the use of advanced computational biology techniques, including molecular modeling, systems biology simulation, and multi-omics data analysis. Companies often rely on these experts to access specialized skills or software they lack, which in turn drives demand for outsourced services.  
   
• The in-house segment accounted for significant revenue in 2024 and is anticipated to grow at a CAGR of 11.2% over the forecast period. Owing to the increasing preference of organizations for secure, customizable, and integrated computational biology solutions that streamline research workflows and protect sensitive data.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the U.S. computational biology market is classified into commercial and academics & research. The commercial segment dominated the market with a revenue share of 62.2% in 2024 and is expected to reach USD 6.3 billion within the forecast period.
 

• Commercial software and platforms provide ready-to-use tools for data analysis, simulation, and modeling. Their ease of deployment and minimal setup requirements encourage adoption by biotech startups, academic labs, and pharma companies, driving market growth.
   
• In addition, commercial solutions enable rapid processing of large-scale biological datasets, such as genomic or proteomic data. High-throughput capabilities save time and reduce manual labor, making these platforms attractive for research and commercial applications.
   
• The academics & research segment held a revenue of USD 1.2 billion in 2024, with projections indicating a steady expansion at 10.5% CAGR from 2025 to 2034. The segmental growth is driven by the expanding use of bioinformatics and computational tools in universities and research institutions for genomics, proteomics, and systems biology studies. Additionally, increased funding for interdisciplinary research and access to high-performance computing resources are boosting adoption in academic settings.
   

Looking for region specific data?

Download Free PDF

South Atlantic Computational Biology Market

South Atlantic dominated the U.S. computational biology market with the highest market share of 20.8% in 2024.
 

• The South Atlantic region hosts prominent universities, research hospitals, and biotech hubs, including in North Carolina, Maryland, and Georgia. This dense concentration of academic and clinical research centres drives demand for computational biology tools and services for genomics, proteomics, and drug discovery projects.
   
• Several leading biotech and pharmaceutical companies have R&D facilities in the South Atlantic states. Their presence increases investment in computational biology platforms and contract services, fostering regional growth and innovation in modeling, simulation, and data analysis.
   
• Furthermore, state governments in the South Atlantic provide grants, tax incentives, and innovation programs to attract biotech firms and support research initiatives. These policies reduce operational costs and encourage investment in computational biology infrastructure and services.
   

Northeast Computational Biology Market

Northeast computational biology market accounted for USD 539.6 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The region benefits from strong venture capital, private equity, and government funding directed toward life sciences and computational biology startups. Ample financial resources enable organizations to invest in cutting-edge platforms, advanced modeling software, and contract research collaborations, accelerating the adoption of computational biology solutions.
   
• Further, there is a strong culture of collaboration between universities, hospitals, and biotech companies in the Northeast. Joint projects often involve shared computational resources, high-performance computing, and co-development of software and simulation models. This interconnected ecosystem drives market growth for commercial platforms and contract services.
   

Pacific Central Computational Biology Market

The Pacific Central computational biology market is anticipated to grow at the highest CAGR of 12.8% during the analysis timeframe.
 

• Leading universities and research institutions in Pacific Central generate large volumes of biological and clinical data. Computational biology tools and contract services are essential for processing, analyzing, and interpreting these datasets. This academic output contributes to regional demand and fosters collaboration with industry players.
   
• Frequent partnerships among biotech firms, academic institutions, and contract research organizations create a collaborative ecosystem for research and development. These networks promote the adoption of commercial platforms, advanced simulation software, and specialized services, reinforcing the region’s position as a leader in computational biology.
   

U.S. Computational Biology Market Share

The market is highly competitive, characterized by the presence of a mix of global life sciences companies, specialized software providers, and innovative biotech startups. Companies are focusing on strategic collaborations, mergers and acquisitions, and technology partnerships to expand their product portfolios and strengthen their market presence. The competitive intensity is further heightened by continuous innovation in AI-driven analytics, multi-omics integration, and high-performance simulation platforms, which are critical for drug discovery, precision medicine, and translational research.
 

Key players include Thermo Fisher Scientific, BIO-RAD, DASSAULT SYSTEMES, Illumina, QIAGEN, and Schrödinger, collectively accounting for 48.2% of the total market share. These leading companies are leveraging advanced software solutions, cloud-based platforms, and contract research services to maintain dominance while continuously enhancing technological capabilities. Their strong R&D focus, extensive customer base, and strategic partnerships enable them to sustain competitive advantages in a rapidly evolving market.
 

Additionally, smaller and emerging players are driving innovation in niche areas, including cellular and biological simulation, AI-based predictive modeling, and multi-omics data analysis. These firms often collaborate with academic institutions and research hospitals to develop specialized solutions, increasing market fragmentation and intensifying competitive pressures. Overall, the landscape is defined by rapid technological evolution, strategic alliances, and continuous investment in computational biology capabilities.
 

U.S. Computational Biology Market Companies

Few of the prominent players operating in the U.S. computational biology industry include:

• Benevolent
• BIO-RAD
• CERTARA
• compugen
• DASSAULT SYSTEMES
• deep genomics
• DNAnexus
• Genedata (Danaher)
• GINKGO
• Illumina
• instem
• QIAGEN
• Schrödinger
• strand
• Thermo Fisher Scientific
   
• Thermo Fisher Scientific

Thermo Fisher Scientific held a leading position in the U.S. computational biology market with a share of around ~15.8% in 2024. Thermo Fisher offers an end-to-end portfolio of laboratory instruments, reagents, and software, enabling seamless integration of experimental and computational workflows. Its strong presence in genomics, proteomics, and bioinformatics provides scalable solutions for both research and clinical applications.
 

• Illumina

Illumina is renowned for its high-throughput sequencing technologies and robust bioinformatics platforms, facilitating rapid and accurate genomic analysis. Its continuous innovation in sequencing and data interpretation positions it as a leader in precision medicine and computational genomics.
 

• QIAGEN

QIAGEN provides comprehensive bioinformatics and molecular biology solutions, including data analysis software and sample preparation kits. Its expertise in multi-omics data integration and translational research supports efficient drug discovery, diagnostics, and personalized medicine initiatives.
 

U.S. Computational Biology Industry News:

• In June 2025, Illumina, Inc. announced that it had entered into a definitive agreement with Standard BioTools to acquire SomaLogic. This development will enhance Illumina's presence in the growing proteomics market. It will aid the company in improving its industry presence.
   
• In December 2024, QIAGEN announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data. This development enabled the company to enhance its service offering and improve the user experience through continuous advancement and updates.
   
• In November 2024, NVIDIA announced the availability of the open-source platform NVIDIA BioNeMo Framework to advance drug discovery and accelerate molecule design. This platform focuses on accelerating and scaling digital biology for different stakeholders in the industry.
   

The U.S. computational biology market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Tool

• Analysis software and services
• Databases
• Hardware

Market, By Application

• Cellular & biological simulation
  • Computational genomics
  • Computational proteomics   
  • Pharmacogenomics
  • Other simulations
• Drug discovery & disease modelling
  • Target identification
  • Target validation
  • Lead discovery
  • Lead optimization
• Preclinical drug development
  • Pharmacokinetics
  • Pharmacodynamics
• Clinical trials
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
• Human body simulation software

Market, By Services

• Contract
• In-house

Market, By End Use

• Commercial
• Academics & research

The above information is provided for the following zones:

• East North Central
• West South Central
• South Atlantic
• Northeast
• East South Central
• West North Central
• Pacific Central
• Mountain States